Aprea reports second partial response in cancer drug trial Feb 18, 2026 08:02AM
Aprea Therapeutics expands patent portfolio for cancer drugs through 2045 Feb 12, 2026 08:30AM
Aprea Therapeutics names Eugene Kennedy as chief medical advisor Feb 4, 2026 08:32AM
Aprea Therapeutics reports partial response in cancer trial Jan 29, 2026 08:29AM
Aprea Therapeutics (APRE) files for 5.5M share offering by selling stockholders Dec 19, 2025 04:13PM


Dec 18, 2025 08:33AM Aprea Therapeutics updates shareholders on clinical programs and 2026 outlook
Nov 12, 2025 04:28PM Aprea Therapeutics (APRE) Misses Q3 EPS by 47c
Oct 24, 2025 08:31AM Aprea Therapeutics reports early activity signals for cancer drug APR-1051
Aug 12, 2025 08:29AM Aprea Therapeutics (APRE) Misses Q2 EPS by 53c
May 14, 2025 04:37PM Aprea Therapeutics (APRE) Misses Q1 EPS by 66c
Apr 17, 2025 07:01AM Adicet Bio (ACET) Appoints Michael Grissinger to the Board of Directors
Mar 25, 2025 04:22PM Aprea Therapeutics (APRE) Misses Q4 EPS by 49c
Mar 11, 2025 08:32AM Aprea Therapeutics (APRE) Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma
Feb 5, 2025 08:01AM Aprea Therapeutics (APRE) Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
Jan 16, 2025 06:53AM H.C. Wainwright Reiterates Buy Rating on Aprea (APRE)
Oct 23, 2024 08:31AM Aprea Therapeutics (APRE) Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics